Publications by authors named "Rob Hagendijk"

Claim this Profile
H
How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases.
Conor M W Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Vololona Rabeharisoa, Wouter Boon

Orphanet J Rare Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constructing a single market for pharmaceuticals in the EU: what's the price?
Tineke Kleinhout-Vliek, Susi Geiger, Rob Hagendijk, Eva Hilberg, Paul Martin

Health Econ Policy Law· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.
Conor M W Douglas, Fernando Aith, Wouter Boon, Marina de Neiva Borba, Liliana Doganova, Rob Hagendijk

Orphanet J Rare Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.
Carla E M Hollak, Marieke Biegstraaten, Matthias R Baumgartner, Nadia Belmatoug, Bruno Bembi, Rob Hagendijk

Orphanet J Rare Dis· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-authorisation assessment of orphan drugs.
Carla E M Hollak, Marieke Biegstraaten, Marcel Levi, Rob Hagendijk

Lancet· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis